— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —

— BioCryst to receive $70M upfront, up to $275M in future regulatory and sales milestone payments, and royalties on sales ranging from 18 to 30 percent —

— Agreement builds upon prior agreement between the two companies for sale of European ORLADEYO® business to Neopharmed Gentili in 2025 —

— Navenibart Phase 3 program in HAE on track for US regulatory filing by end of 2027 —